Systemic autoimmune diseases develop due to impaired regulatory mechanisms and hyperreactive immunity. Autoimmune disorders, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and others are found in 5 to 7% of population. IBC “Generium” develops high-technology biosimilars and original therapeutics for the treatment of autoimmune diseases.
Autoimmune diseases associated with impaired complement activation
Anemia is a pathological condition characterized by decreased level of hemoglobin and (or) erythrocyte count per blood volume unit.Paroxysmal nocturnal hemoglobinuria is a hemolytic anemia developing when the processes of intravascular erythrocyte destruction prevails over their production. It is a consequence of pathological activation of the complement system on the altered erythrocyte membrane. Another severe disorder related to the pathological complement activation is atypical hemolytic-uremic syndrome that is characterized by the damage of small vessels, multiple thrombosis and hemolytic anemia. Despite application of the entire set of modern therapeutic means prognosis for these diseases is often unfavorable. Our company is developing a contemporary , effective and affordable biosimilar therapeutic to treat these disorders.
|GNR-042||Protein based Biosimilar||Preclinical trials in vivo|
|GNR-045||Protein based Biosimilar||Preclinical trials in vivo|